Clinical Trials Logo
  1. Home
  2. Medullary Thyroid Carcinoma
  3. NCT01736878

Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma — SUMMIT  

Medullary Thyroid Carcinoma Clinical Trial

Official title:
Randomized Double-blind Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Sorafenib Treatment in Patients With Advanced (Recurrent, Persistent and/or Metastasizing) Medullary Thyroid Carcinoma

Clinical Trial Summary

The purpose of his study is to evaluate the efficacy and safety of Sorafenib versus placebo in subjects with locally advanced medullary thyroid cancer (MTC). The primary study objective is to compare the Progression-free Survival (PFS) of the Sorafenib treatment group with the placebo treatment group in patients with advanced MTC.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01736878
Study type Interventional
Source Eanm Research Ltd
Contact
Status Withdrawn
Phase Phase 2
Start date October 2012
Completion date April 2013
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03636945 - Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma N/A
Completed NCT06067594 - Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma.
Active, not recruiting NCT04970134 - Spanish Study for Molecular Characterization of Thyroid Carcinoma
Completed NCT01424878 - Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
Completed NCT02586350 - Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) Phase 2/Phase 3
Completed NCT00514046 - Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer Phase 1/Phase 2
Recruiting NCT04787328 - A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) Phase 2
Completed NCT01730638 - ImmunoTEP for Patients With Medullary Thyroid Carcinoma. Phase 1/Phase 2
Enrolling by invitation NCT01511393 - An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
Terminated NCT00923247 - A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) Phase 1/Phase 2
Completed NCT00880503 - Collection of Tissue Samples for Study of Multidrug Resistance
Not yet recruiting NCT06121271 - Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications Phase 2
Completed NCT03246659 - Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC Phase 1
Recruiting NCT05534594 - Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer N/A
Not yet recruiting NCT01373736 - 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Phase 3